274 results on '"Gras, Luuk"'
Search Results
2. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
3. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
4. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
5. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT
6. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
7. Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
8. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
9. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)
10. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT
11. Outcomes of CMML patients undergoing allo‐HCT are significantly worse compared to MDS—a study of the CMWP of the EBMT
12. Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
13. Outcomes of CMML patients undergoing allo‐HCT are significantly worse compared to MDS—a study of the CMWP of the EBMT.
14. Quantification of biological age as a determinant of age-related diseases in the Rotterdam Study : a structural equation modeling approach
15. Correction: Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
16. Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer's disease
17. Sequential vs Myeloablative vs Reduced Intensity Conditioning for Patients with Myelodysplastic Syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: A Retrospective Study by the Chronic Malignancies Working Party of the EBMT
18. From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing
19. Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
20. Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
21. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
22. Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
23. Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
24. Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
25. International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
26. Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia - a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
27. Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1–Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy
28. Increased Virological Failure in Naive HIV-1–Infected Patients Taking Lamivudine Compared With Emtricitabine in Combination With Tenofovir and Efavirenz or Nevirapine in the Dutch Nationwide ATHENA Cohort
29. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT
30. Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
31. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT
32. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
33. Immunodeficiency as a Risk Factor for Non—AIDS-Defining Malignancies in HIV-1—Infected Patients Receiving Combination Antiretroviral Therapy
34. Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT
35. Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP)
36. Discontinuation of Nevirapine Because of Hypersensitivity Reactions in Patients with Prior Treatment Experience, Compared with Treatment-Naive Patients: The ATHENA Cohort Study
37. Autologous Hematopoietic Cell Transplantation For Relapsed Multiple Myeloma Performed With Stem Cells Re-Mobilised Following A Prior AUTO-HCT - A Retrospective Study on Behalf of EBMT CMWP
38. CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time
39. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
40. Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT
41. CD4 cell counts of 800 cells/m[m.sup.3] or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/m[m.sup.3] or greater
42. Mortality in patients with successful initial response to highly active antiretroviral therapy is still higher than in non-HIV-infected individuals
43. Lower incidence of Pneumocystis jirovecii pneumonia among Africans in the Netherlands host or environmental factors?
44. Similar virologic response after initiation of triple-class antiretroviral therapy in primary and chronic HIV infection
45. Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis
46. Long-term complications in patients with poor immunological recovery despite virological successful HAART in Dutch ATHENA cohort
47. Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmission
48. Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control
49. Lower mortality and earlier start of combination antiretroviral therapy in patients tested repeatedly for HIV than in those with a positive first test
50. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.